Evaluating risk of progression and disease-related mortality is an essential first step for all patients with newly diagnosed prostate cancer.
Our goal is to improve the current risk stratification model through developing non-invasive tests that enhances the accuracy in predicting the likely course of the disease. Through careful analysis of serum from patients we have identified several new proteins that is improving current prediction models for aggressive prostate cancer.
One of the candidate biomarkers has been validated in several independent cohorts and we are currently exploring how this biomarker can aid therapy selection.
In parallel we are investigating how this serum protein is affecting tumour tissue, and how this knowledge can improve and individualize patient care.
Project members: Ingrid J. Guldvik, Ian G. Mills (Oxford/Belfast)